To the Editor: With the use of topiramate as a strategy for treatment-resistant bipolar disorder R1628CHDDHFHI—not to mention other off-label uses for conditions such as borderline personality disorder R1628CHDHJDBG and eating disorders R1628CHDJJFDB—clinicians need to be aware of the possibility of topiramate-induced psychosis in patients who have not previously had a psychotic episode. Although there is a small amount of literature in neurology journals regarding psychiatric adverse events in seizure patients R1628CHDBAHHI, the psychiatric literature is largely silent on the subject R1628CHDFBJIF. We report on a patient without a previous history of psychosis who developed psychosis after an increase in his dose of topiramate.

The anticonvulsant topiramate is known to cause cognitive adverse events. Psychiatric adverse events reported in the neurology literature include paranoid delusions, visual and auditory hallucinations, depression, aggressive behavior, and irritability R1628CHDBAHHI. In some case reports of patients with seizure disorder, a decrease in the dose of topiramate resulted in resolution of the psychosis R1628CHDJIGFC. Although no controlled trials have shown topiramate to be adequate for mood stabilization, clinicians need be aware of adverse psychiatric events in patients taking topiramate and consider decreasing the dose or discontinuing the medication altogether.